Chimeric Therapeutics Ltd at NWR Communications Virtual Conference Transcript
Good morning and welcome back to day one of NWR's Virtual Investor Conference Series 11. My name is Max Donne, and I will be your host for today.
Up next this morning, we have Chimeric Therapeutics. Chimeric is developing groundbreaking CAR T cell therapies for solid tumor based on scientific research conducted by leading US CAR T experts.
This morning, we have Chimeric's CEO, Jennifer Chow presenting. (Conference Instructions)
Jennifer, I'll now hand it over to you.
Thanks, Max. Good morning, everybody. Thank you so much for taking the time to join me today. I hope that I will be able to provide a little bit of update for those of you that know us well and some information for those of you that were new too.
Chimeric Therapeutics is a clinical-stage cell therapy company, and we have an incredibly exciting overall investment offer at the moment. We have multiple assets with positive Phase 1 clinical signals. So both are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |